|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gonzalez-Conchas GA, Rodriguez-Romo L,
Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA,
Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, et
al: Epidermal growth factor receptor overexpression and outcomes in
early breast cancer: A systematic review and a meta-analysis.
Cancer Treat Rev. 62:1–8. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pasquale EB: Eph-ephrin bidirectional
signaling in physiology and disease. Cell. 133:38–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Himanen JP, Saha N and Nikolov DB:
Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell
Biol. 19:534–542. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brantley-Sieders DM: Clinical relevance of
Ephs and ephrins in cancer: Lessons from breast, colorectal, and
lung cancer profiling. Semin Cell Dev Biol. 23:102–108. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaenel P, Mosimann M and Andres AC: The
multifaceted roles of Eph/ephrin signaling in breast cancer. Cell
Adh Migr. 6:138–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Genander M and Frisén J: Ephrins and Eph
receptors in stem cells and cancer. Curr Opin Cell Biol.
22:611–616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin B, Yin T, Wu YI, Inoue T and Levchenko
A: Interplay between chemotaxis and contact inhibition of
locomotion determines exploratory cell migration. Nat Commun.
6:66192015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Noren NK, Foos G, Hauser CA and Pasquale
EB: The EphB4 receptor suppresses breast cancer cell tumorigenicity
through an Abl-Crk pathway. Nat Cell Biol. 8:815–825. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janes PW, Griesshaber B, Atapattu L,
Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW,
Bastiaens PI, et al: Eph receptor function is modulated by
heterooligomerization of A and B type Eph receptors. J Cell Biol.
195:1033–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arvanitis D and Davy A: Eph/ephrin
signaling: Networks. Genes Dev. 22:416–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cortina C, Palomo-Ponce S, Iglesias M,
Fernández-Masip JL, Vivancos A, Whissell G, Humà M, Peiró N,
Gallego L, Jonkheer S, et al: EphB-ephrin-B interactions suppress
colorectal cancer progression by compartmentalizing tumor cells.
Nat Genet. 39:1376–1383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pénzváltó Z, Lánczky A, Lénárt J,
Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I and
Győrffy B: MEK1 is associated with carboplatin resistance and is a
prognostic biomarker in epithelial ovarian cancer. BMC Cancer.
14:8372014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Győrffy B, Bottai G, Lehmann-Che J, Kéri
G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H,
et al: TP53 mutation-correlated genes predict the risk of tumor
relapse and identify MPS1 as a potential therapeutic kinase in
TP53-mutated breast cancers. Mol Oncol. 8:508–519. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pongor L, Kormos M, Hatzis C, Pusztai L,
Szabó A and Győrffy B: A genome-wide approach to link genotype to
clinical outcome by utilizing next generation sequencing and gene
chip data of 6,697 breast cancer patients. Genome Med. 7:1042015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bonifaci N, Górski B, Masojć B,
Wokołorczyk D, Jakubowska A, Dębniak T, Berenguer A, Serra Musach
J, Brunet J, Dopazo J, et al: Exploring the link between germline
and somatic genetic alterations in breast carcinogenesis. PLoS One.
5:e140782010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Becker E, Huynh-Do U, Holland S, Pawson T,
Daniel TO and Skolnik EY: Nck-interacting Ste20 kinase couples Eph
receptors to c-Jun N-terminal kinase and integrin activation. Mol
Cell Biol. 20:1537–1545. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stein E, Huynh-Do U, Lane AA, Cerretti DP
and Daniel TO: Nck recruitment to Eph receptor, EphB1/ELK, couples
ligand activation to c-Jun kinase. J Biol Chem. 273:1303–1308.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vindis C, Cerretti DP, Daniel TO and
Huynh-Do U: EphB1 recruits c-Src and p52Shc to activate MAPK/ERK
and promote chemotaxis. J Cell Biol. 162:661–671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chukkapalli S, Amessou M, Dilly AK, Dekhil
H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA,
et al: Role of the EphB2 receptor in autophagy, apoptosis and
invasion in human breast cancer cells. Exp Cell Res. 320:233–246.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Genander M, Halford MM, Xu NJ, Eriksson M,
Yu Z, Qiu Z, Martling A, Greicius G, Thakar S, Catchpole T, et al:
Dissociation of EphB2 signaling pathways mediating progenitor cell
proliferation and tumor suppression. Cell. 139:679–692. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Husa AM, Magić Ž, Larsson M, Fornander T
and Pérez-Tenorio G: EPH/ephrin profile and EPHB2 expression
predicts patient survival in breast cancer. Oncotarget.
7:21362–21380. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lam S, Wiercinska E, Teunisse AF, Lodder
K, ten Dijke P and Jochemsen AG: Wild-type p53 inhibits
pro-invasive properties of TGF-β3 in breast cancer, in part through
regulation of EPHB2, a new TGF-β target gene. Breast Cancer Res
Treat. 148:7–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Poliakov A, Cotrina ML, Pasini A and
Wilkinson DG: Regulation of EphB2 activation and cell repulsion by
feedback control of the MAPK pathway. J Cell Biol. 183:933–947.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dail M, Richter M, Godement P and Pasquale
EB: Eph receptors inactivate R-Ras through different mechanisms to
achieve cell repulsion. J Cell Sci. 119:1244–1254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miao H, Strebhardt K, Pasquale EB, Shen
TL, Guan JL and Wang B: Inhibition of integrin-mediated cell
adhesion but not directional cell migration requires catalytic
activity of EphB3 receptor tyrosine kinase. Role of Rho family
small GTPases. J Biol Chem. 280:923–932. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maddigan A, Truitt L, Arsenault R,
Freywald T, Allonby O, Dean J, Narendran A, Xiang J, Weng A, Napper
S and Freywald A: EphB receptors trigger Akt activation and
suppress Fas receptor-induced apoptosis in malignant T lymphocytes.
J Immunol. 187:5983–5994. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nikolova Z, Djonov V, Zuercher G, Andres
AC and Ziemiecki A: Cell-type specific and estrogen dependent
expression of the receptor tyrosine kinase EphB4 and its ligand
ephrin-B2 during mammary gland morphogenesis. J Cell Sci.
111:2741–2751. 1998.PubMed/NCBI
|
|
33
|
Munarini N, Jäger R, Abderhalden S,
Zuercher G, Rohrbach V, Loercher S, Pfanner-Meyer B, Andres AC and
Ziemiecki A: Altered mammary epithelial development, pattern
formation and involution in transgenic mice expressing the EphB4
receptor tyrosine kinase. J Cell Sci. 115:25–37. 2002.PubMed/NCBI
|
|
34
|
Rutkowski R, Mertens-Walker I, Lisle JE,
Herington AC and Stephenson SA: Evidence for a dual function of
EphB4 as tumor promoter and suppressor regulated by the absence or
presence of the ephrin-B2 ligand. Int J Cancer. 131:E614–E624.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pradeep S, Huang J, Mora EM, Nick AM, Cho
MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, et al:
Erythropoietin stimulates tumor growth via EphB4. Cancer Cell.
28:610–622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, Song C, Huang G, Sun S, Qiao J, Zhao
J, Zhao Z and Li M: The coexpression of EphB4 and EphrinB2 is
associated with poor prognosis in HER2-positive breast cancer. Onco
Targets Ther. 10:1735–1742. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brantley-Sieders DM, Jiang A, Sarma K,
Badu-Nkansah A, Walter DL, Shyr Y and Chen J: Eph/ephrin profiling
in human breast cancer reveals significant associations between
expression level and clinical outcome. PLoS One. 6:e244262011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barneh F, Moshayedi M, Mirmohammadsadeghi
H, Haghjooy-Javanmard S, Sabzghabaee AM and Badri S: EphB4 tyrosine
kinase stimulation inhibits growth of MDA-MB-231 breast cancer
cells in a dose and time dependent manner. Dis Markers. 35:933–938.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Noren NK and Pasquale EB: Paradoxes of the
EphB4 receptor in cancer. Cancer Res. 67:3994–3997. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Steinle JJ, Meininger CJ, Forough R, Wu G,
Wu MH and Granger HJ: Eph B4 receptor signaling mediates
endothelial cell migration and proliferation via the
phosphatidylinositol 3-kinase pathway. J Biol Chem.
277:43830–43835. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Truitt L, Freywald T, DeCoteau J, Sharfe N
and Freywald A: The EphB6 receptor cooperates with c-Cbl to
regulate the behavior of breast cancer cells. Cancer Res.
70:1141–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bhushan L, Tavitian N, Dey D, Tumur Z,
Parsa C and Kandpal RP: Modulation of liver-intestine cadherin
(Cadherin 17) expression, ERK phosphorylation and WNT signaling in
EPHB6 receptor-expressing MDA-MB-231 cells. Cancer Genomics
Proteomics. 11:239–249. 2014.PubMed/NCBI
|
|
43
|
Fox BP and Kandpal RP: EphB6 receptor
significantly alters invasiveness and other phenotypic
characteristics of human breast carcinoma cells. Oncogene.
28:1706–1713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kandpal RP: Tyrosine kinase-deficient
EphB6 receptor-dependent alterations in proteomic profiles of
invasive breast carcinoma cells as determined by difference gel
electrophoresis. Cancer Genomics Proteomics. 7:253–260.
2010.PubMed/NCBI
|
|
45
|
Moshayedi M, Barneh F, Haghjooy-Javanmard
S, Sadeghi HM, Eskandari N and Sabzghabaee AM: A rapid and
sensitive method for EphB4 identification as a diagnostic and
therapeutic biomarker in invasive breast cancer. J Cancer Res Ther.
12:188–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut S, et
al: The somatic mutation profiles of 2,433 breast cancers refines
their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kullander K and Klein R: Mechanisms and
functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol.
3:475–486. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fox BP and Kandpal RP: A paradigm shift in
EPH receptor interaction: Biological relevance of EPHB6 interaction
with EPHA2 and EPHB2 in breast carcinoma cell lines. Cancer
Genomics Proteomics. 8:185–193. 2011.PubMed/NCBI
|
|
50
|
Klein R: Bidirectional modulation of
synaptic functions by Eph/ephrin signaling. Nat Neurosci. 12:15–20.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Orsulic S and Kemler R: Expression of Eph
receptors and ephrins is differentially regulated by E-cadherin. J
Cell Sci. 113:1793–1802. 2000.PubMed/NCBI
|
|
52
|
Paul JM, Toosi B, Vizeacoumar FS,
Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson
DH, Mousseau D, et al: Targeting synthetic lethality between the
SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Oncotarget. 7:50027–50042. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lodola A, Giorgio C, Incerti M, Zanotti I
and Tognolini M: Targeting Eph/ephrin system in cancer therapy. Eur
J Med Chem. 142:152–162. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chrencik JE, Brooun A, Recht MI, Nicola G,
Davis LK, Abagyan R, Widmer H, Pasquale EB and Kuhn P:
Three-dimensional structure of the EphB2 receptor in complex with
an antagonistic peptide reveals a novel mode of inhibition. J Biol
Chem. 282:36505–36513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Koolpe M, Burgess R, Dail M and Pasquale
EB: EphB receptor-binding peptides identified by phage display
enable design of an antagonist with ephrin-like affinity. J Biol
Chem. 280:17301–17311. 2005. View Article : Google Scholar : PubMed/NCBI
|
